In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations

Journal of Nuclear Medicine

Volumn 40, Issue 5, 1999, Pages 829-836

  Steffens, Martijn G ^a   Oosterwijk, Egbert ^a   Kranenborg, Marion H G C ^a   Manders, Jeroen M B ^a   Debruyne, Frans M J ^a   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hydrazinonicotinamide; Mercaptoacetyltriglycine; Monoclonal antibody G250; Radio immunodetection; Renal cell carcinoma

Indexed keywords

BENZOYLMERCAPTOACETYLTRIGLYCINE; CYSTEINE; GLUTATHIONE; HYDRAZINONICOTINAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PENTETIC ACID; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOREACTIVITY; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RADIOISOTOPE DISTRIBUTION; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; IMMUNOGLOBULIN G; ISOTOPE LABELING; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOTECHNETIUM COMPOUNDS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MERTIATIDE; TISSUE DISTRIBUTION;

EID: 0032897936     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mulders P, Figlin R, deKemion JB, et al. Renal cell carcinoma: recent progress and future directions. Cancer Res. 1997;57:5189-5195.
2. DeKernion JB. Renal tumors. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, eds. Campbell's Urology. 6th ed. Philadelphia, PA: WB Saunders; 1993:1294-1342.
3. Delaloye AB, Delaloye B. Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur J Nucl Med. 1995;22:571-580.
4. Goldenberg DM. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer. 1997;80:2431-2435.
5. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131 labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529-1537.
6. Steffens MG, Boerman OC, Oosterwijk E, et al. Phase I/II radioimmunotherapy with I-131 labeled chimeric monoclonal antibody cG250 in patients with metastasized renal cell carcinoma [abstract]. J Nucl Med. 1998;39:247P.
7. 99mTc labeling of highly potent small peptides. Bioconjug Chem. 1997;8:621-636.
8. Mather SJ, Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med. 1990;31:692-697.
9. Oosterwijk E, Ruiter DJ, Hoedemaker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489-494.
10. Oosterwijk E, de Weijert M, van Bokhoven A, Brakenhoff RH, Peelen WP, Debruyne FMJ. Molecular characterization of the renal cell carcinoma associated antigen G250 [abstract]. Urol Res. 1995;23:253.
11. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer. 1993;71:3478-3485.
12. Beniers AJ, Peelen WP, Schaafsma HE, et al. Establishment and characterization of five new human renal tumor xenografts. Am J Pathol. 1992;140:483-495.
13. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022-2028.
14. Fritzberg AR, Abrams PG, Beaumier PL, et al. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA. 1988;85:4025-4029.
15. Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med. 1993;34:1953-1963.
16. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
17. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 1990;50:5531-5536.
18. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
19. Hnatowich DJ, Mardirossian G, Rusckowski M, Fogarasi M, Virzi F, Winnard P Jr. Directly and indirectly technetium-99m-labeled antibodies: a comparison of in vitro and animal in vivo properties. J Nucl Med. 1993;34:109-119.
20. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995;22:42-60.
21. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994;12:1572-1576.
22. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am. 1993;20:283-295.
23. Rhodes BA, Martinez-Duncker C. Direct labeling of antibodies with Tc-99m. Am Biotechnol Lab. 1990;8:50-53.
24. Claessens RA, Boerman OC, Koenders EB, Oyen WJ, van der Meer JW, Corstens FH. Technetium-99m labelled hydrazinonicotinamide human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. Eur J Nucl Med. 1996;23: 414-421.
25. Verbeke KA, Vanbilloen HP, De Roo MJ, Verbruggen AM. Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells. Eur J Nucl Med. 1993;20:473-482.
26. Buist MR, Kenemans P, den Hollander W, et al. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab′)2 fragments in ovarian carcinoma patients. Cancer Res. 1993;53:5413-5418.